| Schedule of Fair Value Measurements on a Recurring Basis |
The Company’s financial assets
subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:
| | |
March 31, 2026 | |
| | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Fair Value | |
| Assets*: | |
| | |
| | |
| | |
| |
| Marketable Securities (see note 3): | |
| | |
| | |
| | |
| |
| DNA | |
| 466 | | |
| - | | |
| - | | |
| 466 | |
| Entera | |
| 130 | | |
| - | | |
| - | | |
| 130 | |
| Pelthos | |
| 3,013 | | |
| - | | |
| - | | |
| 3,013 | |
| Nano | |
| 17,967 | | |
| - | | |
| - | | |
| 17,967 | |
| Nano’s Put options and written Call options, net | |
| - | | |
| 1,356 | | |
| - | | |
| 1,356 | |
| Investments at fair value (see note 4): | |
| | | |
| | | |
| | | |
| | |
| Ruby Capital | |
| - | | |
| - | | |
| 492 | | |
| 492 | |
| Royalty Purchase Agreement | |
| - | | |
| - | | |
| 2,225 | | |
| 2,225 | |
| Tranche A Note | |
| - | | |
| - | | |
| 25,214 | | |
| 25,214 | |
| Tranche B Note | |
| - | | |
| - | | |
| 9,724 | | |
| 9,724 | |
| Warrants Note B | |
| - | | |
| - | | |
| 254 | | |
| 254 | |
| Investment in Alpha Tau’s warrants (see note 8) | |
| - | | |
| - | | |
| 12,000 | | |
| 12,000 | |
| Profit Sharing Loan Agreement | |
| - | | |
| - | | |
| 1,933 | | |
| 1,933 | |
| Loan agreement measured in fair value (see note 7) | |
| - | | |
| - | | |
| 35,412 | | |
| 35,412 | |
| Investment in Alpha Tau’s shares (see note 8) | |
| 102,299 | | |
| - | | |
| - | | |
| 102,299 | |
| Loan to an Equity Method Investee (see note 6) | |
| - | | |
| - | | |
| 423 | | |
| 423 | |
| |
|
$ |
123,875 |
|
|
$ |
1,356 |
|
|
$ |
87,677 |
|
|
$ |
212,908 |
|
| * | As to financial instruments related to the transaction with Lifeward refer to note 9. |
| | |
December 31, 2025 | |
| | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Fair Value | |
| Assets: | |
| | |
| | |
| | |
| |
| Marketable Securities (see note 3): | |
| | |
| | |
| | |
| |
| DNA | |
| 540 | | |
| - | | |
| - | | |
| 540 | |
| Entera | |
| 227 | | |
| - | | |
| - | | |
| 227 | |
| Pelthos | |
| 4,650 | | |
| - | | |
| - | | |
| 4,650 | |
| Nano | |
| 8,371 | | |
| - | | |
| - | | |
| 8,371 | |
| Investments at fair value (see note 4): | |
| | | |
| | | |
| | | |
| | |
| Royalty Purchase Agreement | |
| - | | |
| - | | |
| 2,209 | | |
| 2,209 | |
| Tranche A Note | |
| - | | |
| - | | |
| 23,063 | | |
| 23,063 | |
| Warrants Note B | |
| - | | |
| - | | |
| 850 | | |
| 850 | |
| Tranche B Note | |
| - | | |
| - | | |
| 11,473 | | |
| 11,473 | |
| Loan agreement measured in fair value (see note 7) | |
| - | | |
| - | | |
| 27,943 | | |
| 27,943 | |
| Investment in Alpha Tau’s warrants (see note 8) | |
| - | | |
| - | | |
| 6,242 | | |
| 6,242 | |
| Profit Sharing Loan Agreement | |
| - | | |
| - | | |
| 1,890 | | |
| 1,890 | |
| Investment in Alpha Tau’s shares (see note 8) | |
| 71,623 | | |
| - | | |
| - | | |
| 71,623 | |
| Loan to an equity method investee (see note 6) | |
| - | | |
| - | | |
| 553 | | |
| 553 | |
| Convertible note (see note 9) | |
| - | | |
| - | | |
| 4,636 | | |
| 4,636 | |
| | |
$ | 85,411 | | |
$ | - | | |
$ | 78,859 | | |
$ | 164,270 | |
|